Obermatt
See Similar Stocks →

Elanco Animal Health

NYQ:ELAN · US28414H1032
PharmaceuticalsX-Large

360

10
EV / EBIT41
Price / Owner Earnings11
Owner Earnings Yield12
Dividend Yield1
Price/Sales69
EV / Gross Profit44
Price/Book63
Return on Capital9
Cash Return on Capital6
Return on Equity9
EBIT Margin8
Gross Profitability14
Accruals83
Owner Earnings Margin6
Sales growth53
Profit Growth93
Long-Term EPS Growth60
Owner Earnings Growth1
Reinvestment13
Price momentum74
Debt load28
Refinancing92
Debt Payback3
Liquidity49
Analyst ratings43
Opinion Changes55
Price Target Upside72
Market mood52
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Elanco Animal Health clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded2018
Employees7,093
Websiteelanco.com
ISINUS28414H1032
Last UpdateApr 2, 2026
Indices
S&P MIDCAP (USA)D.J. US Health CareD.J. US Pharmaceutical
Themes
Pet CarePain ManagementCardiovascularAnimal FeedLivestockPet Food and SuppliesVaccines

Description

Elanco Animal Health Incorporated (Elanco), together with its subsidiaries, operates as a global company in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The compan…

Analysis

Weak and unloved

Elanco Animal Health Incorporated is weak and unloved: below-average business metrics and a price that reflects that disappointment.

The price is expensive. You pay 75.3× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 24% yearly growth; analysts expect 12%. The market is pricing in far more than analysts expect: heroic expectations.

The trajectory is moderate and the balance sheet is fragile. The company scores 12/20 on our value-creation score: creating some value.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
62
2023202420252026

All-time high

100

Feb 2026

All-time low

26

Jan 2025

Average rank

58

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
69
66
58
52
Price/Earnings
19
60
38
45
Price/Book
63
76
68
74
Dividend Yield
1
1
1
1
Value (overall)
45
72
48
51

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Elanco Animal Health with its peers
Zoetis
NYQ:ZTS
56
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Phibro Animal Health
NMQ:PAHC
59
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
OmniAb
NMQ:OABI
61
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Pfizer Limited
NSI:PFIZER
65
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Veru
NAQ:VERU
23
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →